ES2598277T3 - Hidralazina para su uso en el tratamiento de la degeneración macular asociada a la edad - Google Patents

Hidralazina para su uso en el tratamiento de la degeneración macular asociada a la edad Download PDF

Info

Publication number
ES2598277T3
ES2598277T3 ES12173008.9T ES12173008T ES2598277T3 ES 2598277 T3 ES2598277 T3 ES 2598277T3 ES 12173008 T ES12173008 T ES 12173008T ES 2598277 T3 ES2598277 T3 ES 2598277T3
Authority
ES
Spain
Prior art keywords
compound
macular degeneration
administration
subject
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES12173008.9T
Other languages
English (en)
Spanish (es)
Inventor
George C. Chiou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas A&M University System
Original Assignee
Texas A&M University System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A&M University System filed Critical Texas A&M University System
Application granted granted Critical
Publication of ES2598277T3 publication Critical patent/ES2598277T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES12173008.9T 2005-05-12 2006-05-04 Hidralazina para su uso en el tratamiento de la degeneración macular asociada a la edad Expired - Lifetime ES2598277T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US68099805P 2005-05-12 2005-05-12
US680998P 2005-05-12
US77642606P 2006-02-24 2006-02-24
US776426P 2006-02-24
US11/416,773 US8088773B2 (en) 2005-05-12 2006-05-03 Therapeutic compositions and methods
US416773 2006-05-03

Publications (1)

Publication Number Publication Date
ES2598277T3 true ES2598277T3 (es) 2017-01-26

Family

ID=37431545

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12173008.9T Expired - Lifetime ES2598277T3 (es) 2005-05-12 2006-05-04 Hidralazina para su uso en el tratamiento de la degeneración macular asociada a la edad

Country Status (9)

Country Link
US (5) US8088773B2 (enExample)
EP (3) EP2508183B1 (enExample)
JP (2) JP5335419B2 (enExample)
AU (1) AU2006247892B2 (enExample)
CA (1) CA2608163C (enExample)
DE (1) DE202006020318U1 (enExample)
ES (1) ES2598277T3 (enExample)
PL (1) PL2508182T3 (enExample)
WO (1) WO2006124324A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007238677B2 (en) * 2006-04-14 2011-03-10 Novartis Ag Use of IL-I antibodies for treating ophthalmic disorders
US7736860B2 (en) * 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
GB0625270D0 (en) * 2006-12-19 2007-01-31 Univ Leicester Angiogenesis
WO2011025734A1 (en) 2009-08-24 2011-03-03 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
US9254287B2 (en) 2012-06-11 2016-02-09 Macuclear, Inc. Therapeutic formulation and methods of treatment
US9259420B2 (en) * 2012-09-13 2016-02-16 Cba Pharma, Inc. Tetrandrine pharmaceutical formulations
EP3026054B1 (en) 2013-07-23 2019-03-06 Eisai R&D Management Co., Ltd. Hetero-condensed ring compound
US9370503B1 (en) * 2015-02-26 2016-06-21 Chi Chou Liao Compounds for treating ocular diseases
AU2018383598B2 (en) 2017-12-11 2024-03-07 Artelo Biosciences, Inc. New solid forms of cannabidiol and uses thereof
US10632211B2 (en) * 2018-06-11 2020-04-28 The Regents Of The University Of California Demethylation to treat eye disease
CN110585196B (zh) * 2018-06-13 2022-11-04 郭涛 一种治疗及预防眼科疾病的药物及其应用
CN112007031A (zh) * 2019-05-30 2020-12-01 杏国新药股份有限公司 眼用制剂
EP3949958A1 (en) * 2020-08-04 2022-02-09 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound for the treatment and prophylaxis of a lipofuscin-associated disease
CN114276251B (zh) * 2021-12-07 2022-12-16 武汉大学 一种合成硝基(杂)芳烃的方法
US20240285572A1 (en) * 2023-02-27 2024-08-29 Opticgon Llc Compositions comprising nitric oxide-releasing compounds for treating choroidal vascular diseases and methods of their use

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4055645A (en) * 1976-02-13 1977-10-25 Merck & Co., Inc. Novel anti-hypertensive compositions
US4865599A (en) * 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
FI873428A7 (fi) * 1986-08-18 1988-02-19 Houston Biotechnology Incorporated Silmälääketieteelliset koostumukset hermodegeneraatioiden hoitoon.
IT1201151B (it) * 1987-01-14 1989-01-27 Indena Spa Complessi fosfolipidici con estratti da vitis vinifera,procedimento per la loro preparazione e composizioni che li cntengono
US5500230A (en) * 1987-01-23 1996-03-19 The General Hospital Corporation Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5194434A (en) * 1991-12-03 1993-03-16 Texas A&M University System Use of OB-101 to treat ocular inflammation
US5252607A (en) * 1992-01-24 1993-10-12 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5422166A (en) * 1993-02-12 1995-06-06 Wangner Systems Corporation Abrasion resisting edge for a forming fabric
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5596011A (en) * 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
EP0911027A4 (en) * 1996-04-26 2000-11-29 Fujisawa Pharmaceutical Co THE DIHYDROPYRIDINE CONTAINS TO IMPROVE THE CIRCULATION OF THE EYE-SURROUNDING TISSUE
WO1998010758A1 (en) * 1996-09-13 1998-03-19 The Regents Of The University Of California Methods for treatment of retinal diseases
JP4828670B2 (ja) * 1996-10-28 2011-11-30 千寿製薬株式会社 眼循環障害改善剤
CA2323749A1 (en) * 1998-03-06 1999-09-10 William E. Sponsel Composition and method for treating macular disorders
US6028099A (en) * 1998-03-13 2000-02-22 John Hopkins University, School Of Medicine Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization
WO2000000194A1 (en) * 1998-06-27 2000-01-06 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
EP1161686A2 (en) * 1999-03-05 2001-12-12 University Of Iowa Research Foundation Diagnostics and therapeutics for drusen associated ocular disorders
IL137429A0 (en) * 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
AU779991B2 (en) * 1999-08-10 2005-02-24 Board Of Regents, The University Of Texas System Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
JP4372905B2 (ja) * 1999-09-02 2009-11-25 興和株式会社 網膜神経細胞保護剤
US20030007971A1 (en) * 2000-01-31 2003-01-09 Hideaki Hara Remedies for ophthalmic diseases
EP2241328A1 (en) * 2000-05-12 2010-10-20 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
US6692759B1 (en) * 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
US20030171375A1 (en) * 2002-02-13 2003-09-11 Brazzell Romulus Kimbro Method for treating ocular neovascular diseases
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
WO2004042353A2 (en) * 2002-10-30 2004-05-21 Galileo Pharmaceuticals, Inc. Identifying therapeutic compounds based on their physical-chemical properties
JP2004250347A (ja) * 2003-02-18 2004-09-09 Ajinomoto Co Inc 網膜虚血に基づく疾患の治療および／又は予防剤
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2006052899A2 (en) * 2004-11-08 2006-05-18 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders

Also Published As

Publication number Publication date
EP2508182B1 (en) 2016-07-06
EP2508182A1 (en) 2012-10-10
WO2006124324A1 (en) 2006-11-23
EP1885371A4 (en) 2010-04-07
DE202006020318U1 (de) 2008-07-31
HK1177419A1 (en) 2013-08-23
EP2508183A1 (en) 2012-10-10
PL2508182T3 (pl) 2017-05-31
AU2006247892B2 (en) 2010-04-22
US20130059841A1 (en) 2013-03-07
AU2006247892A1 (en) 2006-11-23
JP2008540528A (ja) 2008-11-20
US20060276458A1 (en) 2006-12-07
JP2012229257A (ja) 2012-11-22
CA2608163C (en) 2011-10-25
EP1885371A1 (en) 2008-02-13
CA2608163A1 (en) 2006-11-23
US20120196868A1 (en) 2012-08-02
US20120071485A1 (en) 2012-03-22
US8318741B2 (en) 2012-11-27
EP2508183B1 (en) 2014-07-09
US8088773B2 (en) 2012-01-03
JP5335419B2 (ja) 2013-11-06
JP5643263B2 (ja) 2014-12-17
US20120115959A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
ES2935605T3 (es) Combinaciones de cannabinoides y N-aciletanolaminas
ES2257768T3 (es) Antagonistas de neurotropina para el tratamiento de epilepsia, enfermedad de alzheimer y el dolor.
ES2372421T3 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopáusicos.
US20060204486A1 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
US20120010288A1 (en) Method for protecting a retinal neuronal cell
ES2673158T3 (es) Nuevo agente terapéutico para la esclerosis lateral amiotrófica (ELA) o enfermedad atribuible a ELA
KR20010071827A (ko) 반점성망막 퇴행에서 신혈관 신생의 예방치료
AR045040A1 (es) Derivados de compuestos espiroazabiciclicos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos
JP2005533766A (ja) アレルギー反応の治療方法
ES2546672T3 (es) Formulación acuosa estable mejorada de (E)-4-carboxiestiril-4-clorobencilsulfona
ES3006014T3 (en) Use of nalfurafine for the treatment of demyelinating diseases
KR100342367B1 (ko) 녹내장치료제및안압강하제
US11622954B2 (en) Estrogen receptor ligands, compositions and methods related thereto
US12521387B2 (en) Prophylactic or therapeutic drug for neurodegenerative diseases
TW202220666A (zh) 含有賽佩普斯特（ｓｅｐｅｔａｐｒｏｓｔ）之醫藥製劑
US20040039003A1 (en) Treatment of hepatic cirrhosis
BR112021005955A2 (pt) agentes e métodos para modular atividade de patógeno
JP2021504400A (ja) シグマ−１受容体アゴニスト収縮期血圧療法
WO2005055997A1 (ja) 炎症性疾患の治療及び予防用医薬組成物
CA2192576A1 (en) Remedy for allergic diseases in the region of the nose
IL93243A (en) Preparations for the prevention of neurodegeneration
JP4695326B2 (ja) 鼻炎用医薬組成物
EP2599480A1 (en) Compounds for the treatment of influenza
JP2009235093A (ja) 鼻炎用医薬組成物
ES2341517B1 (es) Utilizacion de un compuesto inhibidor de la activacion de la enzima erk 1/2 en el tratamiento de enfermedades neurodegenerativas.